CLINICAL TRIALS PROFILE FOR IMAGABALIN
✉ Email this page to a colleague
Clinical Trials for Imagabalin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00542685 ↗ | A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder | Completed | Pfizer | Phase 3 | This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder. |
NCT00658008 ↗ | A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) | Terminated | Pfizer | Phase 3 | This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder. |
NCT00658372 ↗ | A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) | Terminated | Pfizer | Phase 3 | This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder. |
NCT00658762 ↗ | A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) | Terminated | Pfizer | Phase 3 | This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects ages 18 and older with generalized anxiety disorder. |
NCT00721422 ↗ | A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function. | Terminated | Pfizer | Phase 1 | 1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body. 2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function. |
NCT00730145 ↗ | A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis | Completed | Pfizer | Phase 1 | 1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis. |
NCT00800280 ↗ | Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body | Terminated | Pfizer | Phase 1 | The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Imagabalin
Condition Name
Clinical Trial Locations for Imagabalin
Trials by Country
Clinical Trial Progress for Imagabalin
Clinical Trial Phase
Clinical Trial Sponsors for Imagabalin
Sponsor Name